Get the Daily Brief
Latest Biotech News
Deep learning revs antibiotic discovery: two Nature Biotechnology reads
Two independent Nature Biotechnology papers detail how deep‑learning approaches accelerated antibacterial discovery. One study combined phenotypic screening with deep neural networks to prioritize...
LNP anatomy revealed: biophysics links particle shape to delivery
A multidisciplinary team at the University of Pennsylvania, Brookhaven National Laboratory and collaborators mapped lipid nanoparticle (LNP) structures and linked distinct morphologies to delivery...
Retrons retooled: metagenomes yield new retron gene editors
Researchers mined bacterial and archaeal metagenomes to identify self‑priming retrons that function as DNA donors and adapted several as programmable gene editors compatible with CRISPR systems....
Moderna’s CMV vaccine misses: pivotal failure halts program
Moderna disclosed that its mRNA‑1647 cytomegalovirus (CMV) vaccine failed to meet the primary efficacy endpoint in the Phase III CMVictory trial in seronegative females aged 16–40. The company...
Tango advances PRMT5 candidate: Phase III and $225M to push pancreatic program
Tango Therapeutics announced plans for a pivotal Phase III study of vopimetostat (TNG‑462), a next‑generation PRMT5 inhibitor designed to exploit MTA cooperativity in MTAP‑deleted tumors, based on...
Biogen stakes $70M on Vanqua C5aR1 antagonist — immunology push
Biogen struck an exclusive global licensing deal with Vanqua Bio, paying $70 million up front for a preclinical C5aR1 antagonist and reserving up to roughly $990 million in downstream milestones....
Lilly scoops Adverum — buys phase‑3 eye gene therapy at bargain price
Eli Lilly agreed to acquire Adverum in a deal that transfers the company’s phase‑3 intravitreal gene therapy ixo‑vec to Lilly as Adverum faced cash depletion. Lilly’s upfront is modest relative to...
FDA clears GSK’s Blenrep — U.S. return comes with limits
The U.S. Food and Drug Administration approved GSK’s antibody–drug conjugate Blenrep for a narrower set of multiple myeloma patients and regimens than the company requested. The agency’s decision...
Tango pivots PRMT5 into pivotal PDAC study — raises $225M to fund push
Tango Therapeutics unveiled encouraging phase I/II data for its MTA‑cooperative PRMT5 inhibitor vopimetostat in MTAP‑deleted pancreatic ductal adenocarcinoma, and contemporaneously raised $225...
AI accelerates antibiotic discovery — two Nature Biotechnology reports
Two complementary papers published in Nature Biotechnology demonstrate that deep‑learning approaches can materially accelerate antibacterial discovery by prioritizing novel scaffolds from...
10x, Roche and Prognosys sue Illumina over spatial and single‑cell patents
A consortium led by 10x Genomics, together with Roche Sequencing Solutions and Prognosys, filed federal lawsuits accusing Illumina of infringing multiple patents covering spatial‑transcriptomics...
Moderna halts CMV vaccine after Phase III miss
Moderna reported that its cytomegalovirus (CMV) mRNA vaccine mRNA‑1647 failed to meet the primary efficacy endpoint in a pivotal Phase III trial and stopped development of the program. The Phase...
Ventyx’s oral NLRP3 inhibitor shows cardiovascular biomarker gains — partnership talks begin
Ventyx Biosciences released Phase II data showing its oral NLRP3 inhibitor produced rapid and sustained reductions in hsCRP and other inflammation‑related biomarkers in patients with obesity and...
Inhibrx posts phase II win in rare chondrosarcoma — BLA filing eyed
Inhibrx reported that ozekibart (INBRX‑109), its monoclonal antibody, met the primary endpoint in a registrational Phase II trial for unresectable or metastatic chondrosarcoma, delivering a...
Biophysics maps LNP shapes — route to tissue‑targeted RNA delivery
A multidisciplinary team delineated the detailed shapes and structural heterogeneity of lipid nanoparticles (LNPs) used for RNA delivery, linking particle architecture to delivery performance....
Biogen pays $70M upfront for Vanqua C5aR1 – up to $1B more
Biogen signed an exclusive worldwide license with Vanqua Bio, paying $70 million up front for preclinical C5aR1 antagonist VQ-201 and agreeing to as much as $990 million in milestone payments....
Lilly buys Adverum for eye-gene therapy assets – contingent-value rights included
Eli Lilly agreed to acquire Adverum Biotechnologies to secure ixo-vec, an intravitreal AAV gene therapy in a Phase 3 study for wet age-related macular degeneration. The transaction pays Adverum...
FDA clears GSK’s Blenrep in limited multiple myeloma use – mixed ruling
The U.S. Food and Drug Administration approved GSK’s antibody–drug conjugate Blenrep for a narrowed multiple myeloma indication after a complex regulatory review. The agency cleared Blenrep for...
Ventyx’s NLRP3 inhibitor slashes inflammation marker 78% in Phase 2 – shares surge
Ventyx Biosciences reported Phase 2 data showing oral NLRP3 inhibitor VTX3232 produced rapid and large reductions in high-sensitivity C-reactive protein (hsCRP), with a 78% decline versus placebo...
Tango to move PRMT5 inhibitor into Phase 3 for MTAP‑deleted pancreatic cancer – $225M raise
Tango Therapeutics announced it will launch a pivotal Phase 3 study of vopimetostat (TNG‑462), a next‑generation PRMT5 inhibitor designed to exploit MTAP-deleted tumors, after positive Phase 1/2...